Standout Papers

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, ... 2008 2026 2014 2020 509
  1. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 (2008)
    Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Renal cell carcinoma
2024 Standout
Rational Design in Photopharmacology with Molecular Photoswitches
2023 StandoutNobel
6 intermediate papers

Works of Karin Amundson being referenced

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
2008 Standout

Author Peers

Author Last Decade Papers Cites
Karin Amundson 424 327 25 255 14 768
C.S. Cooper 475 211 25 254 17 929
Robert McKinstry 473 432 127 83 20 964
Songbo Qiu 474 354 44 120 26 851
Shengnan Yu 359 481 34 236 24 876
Juliet Williams 474 257 28 108 14 692
Allison Landman 692 441 16 185 15 937
Urszula M. Polanska 480 421 32 219 29 862
Kee Ming Chia 438 378 23 150 19 760
Cynthia Bedell 446 252 49 100 11 732
Heiko Maacke 650 489 30 151 21 893

All Works

Loading papers...

Rankless by CCL
2026